Methods: In this prospective phase II/III trial, up to 1,912 pts with resected stage III A, B (all pts) and stage II, IIIC (ctDNA+ only) CC will be enrolled. Based on the post-operative ctDNA status using personalized and tumor-informed assay (Signatera, bespoke assay), those who ...
Support: U10-CA-180868, -180822; UG1CA-189867;Clinical trial information: NCT05174169.doi:10.1200/JCO.2022.40.16_suppl.TPS3643Arvind DasariThe University of Texas MD Anderson Cancer Center, Houston, TX;Yan LinThe University of Pittsburgh, Pittsburgh, PA;Scott Kopetz...
At five and ten years, the rate of late grade 3 GI/GU AEs was 4% and 5%, respectively.Five- and ten-year overall survival rates were 95% and 76%. Biochemical failure rates per Phoenix definition at five and ten-years were 14% and 23%. The ten-year rate of disease-specific ...